Dornan David 4

What Happened

• David Dornan, Chief Scientific Officer of Whitehawk Therapeutics (WHWK), was granted 282,340 derivative shares (award/acquisition) on April 1, 2026. The reported acquisition price is $0.00, indicating an equity award rather than an open‑market purchase; no cash changed hands in this transaction. The award is subject to vesting conditions described below.

Key Details

• Transaction date: April 1, 2026; Form 4 filed April 3, 2026 (appears to be timely relative to a two‑business‑day filing window).
• Transaction type/code: A — Grant, award or other acquisition (derivative securities).
• Shares granted: 282,340; reported price: $0.00; total reported value: $0 (derivative award).
• Shares owned after transaction: Not specified in the filing.
• Footnote (vesting): 25% of the award vests on the one‑year anniversary of the Vesting Commencement Date (April 1, 2027), then 1/48th of the total shares vests each month thereafter, so the award is fully vested on the four‑year anniversary (April 1, 2030). Vesting is conditioned on continued service as a Service Provider under the issuer’s 2021 Equity Incentive Plan.

Context

• This is an equity grant to an executive (not a market purchase or sale). Because the award vests over time and is contingent on continued service, it does not represent an immediate cash investment or divestiture by the insider. Such grants are common as part of compensation packages and primarily reflect long‑term incentive alignment rather than near‑term trading intent.